ANI Pharmaceuticals, Inc. (ANIP)

US — Healthcare Sector
Peers: EGRX  PAHC  DCPH  PBH  ALKS  RDY  COLL  PCRX  PROC  SSIC  NBIX  AMPH  IRWD  INCR 

Automate Your Wheel Strategy on ANIP

With Tiblio's Option Bot, you can configure your own wheel strategy including ANIP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ANIP
  • Rev/Share 34.3789
  • Book/Share 22.6179
  • PB 2.8046
  • Debt/Equity 0.7585
  • CurrentRatio 2.6573
  • ROIC 0.0047

 

  • MktCap 1296467868.0
  • FreeCF/Share 3.4869
  • PFCF 18.9634
  • PE -55.7805
  • Debt/Assets 0.2457
  • DivYield 0
  • ROE -0.0486

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ANIP Jefferies -- Buy -- $80 March 14, 2025
Initiation ANIP JP Morgan -- Overweight -- $85 March 12, 2025
Initiation ANIP Leerink Partners -- Outperform -- $80 Dec. 11, 2024
Initiation ANIP Piper Sandler -- Overweight -- $68 Oct. 11, 2024

News

Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
ANIP
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive

Here is how ANI Pharmaceuticals (ANIP) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.

Read More
image for news Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe
ANIP
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval of Purified Cortrophin® Gel (repository corticotropin injection USP) (Cortrophin Gel) in a prefilled syringe format. This new presentation will be available in 40 USP units/0.5 mL and 80 USP units/mL single-dose options through Cortrophin Gel's established specialty pharmacy network. The prefilled syringe reduces administration steps for patients using Cortrophin Gel, which remains available in 5 mL and 1 mL vials. For full indications and important safety information, please see below.

Read More
image for news ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe
ANI Pharmaceuticals, Inc. (ANIP) Q4 2024 Earnings Call Transcript
ANIP
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q4 2024 Earnings Conference Call February 28, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants David Amsellem - Piper Sandler Vamil Divan - Guggenheim Securities Gary Nachman - Raymond James Faisal Khurshid - Leerink Partners Oren Livnat - H.C. Wainwright Jeevan Larson - Truist Securities Glen Santangelo - Jefferies Operator Good morning, everyone.

Read More
image for news ANI Pharmaceuticals, Inc. (ANIP) Q4 2024 Earnings Call Transcript
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance
ANIP
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

BAUDETTE, Minn., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the fourth quarter and full year ended December 31, 2024.

Read More
image for news ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance
ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March
ANIP
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and select members of senior management, will present at two upcoming investor conferences as follows: Raymond James & Associates' 46 th Annual Institutional Investors Conference Tuesday, March 4, 2025, at 1:40pm ET Leerink Partners Global Healthcare Conference Tuesday, March 11, 2025, at 3:40pm ET The live and archived webcasts will be accessible from the Company's website at www.anipharmaceuticals.com , under the Investors section under Events and Presentations.

Read More
image for news ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March

About ANI Pharmaceuticals, Inc. (ANIP)

  • IPO Date 2000-05-05
  • Website https://www.anipharmaceuticals.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Mr. Nikhil Lalwani
  • Employees 897

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.